Search

Marcin Borowicz received a NAWA Bekker award (2025 edition) of PLN 288,500 for a two-year project at the Australian Centre for Ecogenomics, University of Queensland, Brisbane. “Ecogenomics of tailocins: viral legacy in microbial interaction

A $3.3 million NIAID contract supports a proof-of-concept clinical trial of LBP-PA01 for pneumonia, with further funding conditional on milestones. www.locus-bio.com

Dr Piotr Golec of the Department of Molecular Virology, Institute of Microbiology, Faculty of Biology UW has received PLN 1,881,850 from the National Science Centre (NCN) under its OPUS 29 call for a project on interactions between lytic ph

UMC Utrecht has received a 4 million euro grant from the Promising Care scheme of the National Healthcare Institute and ZonMw for the first clinical study in the Netherlands of customized bacteriophage therapy for recurrent urinary tract in

A team of Imperial scientists from Life Sciences and Medicine has received approximately £2.7 million through a Wellcome Trust Discovery Award to study capsid-forming phage-inducible chromosomal islands (cf-PICIs), which release tail-less c

Baylor University will partner with academic and industry investigators on MIGHTY, a five-year initiative funded up to $28 million by ARPA-H. The project aims to develop a precision phage platform, starting with oral health. Aaron Wright wi

Paris-based Phagos has raised a €25 million Series A co-led by CapAgro, Hoxton Ventures, CapHorn and Demeter. The funds will go to deploying its veterinary phage treatments in the field, developing the next generation of its AI phage-discov

MicrobiotiX, a Korean bacteriophage-therapy company, completed an extended Series B totaling 20 billion KRW (29 billion KRW raised across rounds). It was also selected for the Korean Ministry of Health and Welfare's Infectious Disease Preve

Lake Forest College alumna Laurel Robbins (’23), a PhD candidate in biochemistry at the University of Colorado Boulder, received a 2025 National Science Foundation Graduate Research Fellowship, securing funding for tuition, stipend and fees

CARB-X awarded PHIOGEN $1.1 million to evaluate PHI-BI-01, a phage-based candidate designed to treat and prevent ExPEC bloodstream infections. The project aims to pair immediate treatment with longer-term immune protection. CARB-X

Precisio Biotix Therapeutics (Delaware-based biotech) announced a newly awarded Gates Foundation grant for engineered lysin discovery targeting bacterial vaginosis.

Navy Medicine Research & Development reports that, over a six-year Congressionally Directed Medical Research Programs (CDMRP) award starting in fiscal year 2019, the Naval Medical Research Command worked with the U.S. Naval Research Laborat

The European Commission’s 2025 call sought multicentre, multinational randomised trials of phage therapies for difficult-to-treat bacterial infections, alone or alongside standard care. The call is closed; its deadline was September 16, 202

Qeen Biotechnologies (in partnership with Cellexus, CPI, University of Exeter, NRC Canada, and Unity Health Toronto) was awarded a $2M CAD grant through the Canada–UK: Biomanufacturing of Biologics and Advanced Therapies program to develop

After an announcement last month that Canada would close its phage therapy research program at the National Microbiology Lab in Winnipeg, Michael Parcey and colleagues have announced a ‘stunning reversal’: a set of unexpected, last-minute c

PrecisionPhage raised €1 million from Nordic Science Investment, Genetricum and Unifund and secured €1.2 million in Deep Tech Accelerator funding from Business Finland, a €2.2 million seed round. The company develops bioinformatic tools for

DARPA seeks a Program Manager to lead and manage high-risk, high-reward research programs in emerging technologies. (*We need more phage people in these roles! Plus you get to work with Mike Koeris!)

Boston University is hiring an Alliance Director to lead CARB-X phage research and development initiatives, including helping manage CARB-X’s prevention portfolio, which includes projects involving vaccines, live biotherapeutics, phage and

The ADVANcing Clinical Evidence in Infectious Diseases (ADVANCE-ID) Network is offering funding for Phase II or III clinical trials focusing on antimicrobial agents for multi-resistant Gram-negative bacilli infections. Application deadline

Micreos, a Dutch/Swiss biotech company, has secured its next funding round of €25 million in growth capital for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.